It’s official: Controversial Marathon Pharmaceuticals bows out at PhRMA in wake of price gouging controversy
A controversial Marathon Pharmaceuticals is out at PhRMA.
Two months ago Marathon triggered a storm of controversy when it took an old, cheap steroid from overseas — deflazacort — and bagged an FDA approval for Duchenne muscular dystrophy largely on decades-old efficacy data acquired for a bargain basement rate. The company priced it at $89,000 a year, sparking a backlash from Duchenne parents who were buying it for about $1,000 annually.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
